Trial Profile

Phase I trial of CB 008 in patients with Ebola virus infections in West Africa

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 22 Jan 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CB 008 (Primary)
Indications Ebola virus infections
Focus Adverse reactions
Sponsors Canopus BioPharma

Most Recent Events

22 Jan 2015 New trial record
19 Dec 2014 This trial in West Africa is expected to be initiated after an Ebola study in primates, according to a Canopus BioPharma media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com